Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2014 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Other Non-Current Liabilities of $5.9 million for Q1 2026, down 75.73% year-over-year from $24.4 million in Q1 2025, and little changed quarter-over-quarter from $5.9 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 75.73% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 75.73% YoY), while the FY2025 annual figure was $5.9 million, down 71.71% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $5.9 million, roughly flat from $5.9 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $27.0 million in Q3 2024, with the low at $5.9 million in Q4 2025.
- The 5-year median for Other Non-Current Liabilities is $14.2 million (2022), against an average of $13.2 million.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities jumped 274.21% in 2024, then plunged 75.73% in 2026.
- Amphastar Pharmaceuticals' Other Non-Current Liabilities stood at $7.2 million in 2022, then fell by 16.04% to $6.1 million in 2023, then jumped by 245.29% to $20.9 million in 2024, then plunged by 71.71% to $5.9 million in 2025, then changed by 0.0% to $5.9 million in 2026.
- Business Quant data shows AMPH's Other Non-Current Liabilities at $5.9 million in Q1 2026, $5.9 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Amphastar Pharmaceuticals | 949.26 Mn | 659.13 Mn | 93.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.44 Mn |
| Mar 31, 2026 | 5.93 Mn |
| Dec 31, 2025 | 5.93 Mn |
| Sep 30, 2025 | 6.96 Mn |
| Jun 30, 2025 | 6.96 Mn |
| Mar 31, 2025 | 24.42 Mn |
| Dec 31, 2024 | 20.95 Mn |
| Sep 30, 2024 | 27.04 Mn |
| Jun 30, 2024 | 18.80 Mn |
| Mar 31, 2024 | 17.98 Mn |
| Dec 31, 2023 | 6.07 Mn |
| Sep 30, 2023 | 7.23 Mn |
| Jun 30, 2023 | 17.63 Mn |
| Mar 31, 2023 | 15.18 Mn |
| Dec 31, 2022 | 7.23 Mn |
| Sep 30, 2022 | 14.19 Mn |
| Jun 30, 2022 | 6.53 Mn |
| Mar 31, 2022 | 15.49 Mn |
| Dec 31, 2021 | 15.65 Mn |
| Sep 30, 2021 | 14.88 Mn |